Attention level and event-related evoked potentials in patients with cerebrovascular disease treated with amantadine sulfate - A pilot study

Advances in Clinical and Experimental Medicine

Volumn 17, Issue 5, 2008, Pages 553-558

  Pokryszko Dragan, Anna ^a   Słotwiński, Krzysztof ^a   Budrewicz, Sławomir Piotr ^a   Podemski, Ryszard ^a   Zagrajek, Mieszko ^a   Bilińska, Małgorzata ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Amantadine sulfate; Cerebrovascular disease; Cognitive dysfunction; Event related potentials

Indexed keywords

AMANTADINE SULFATE;

ACTION POTENTIAL; ADULT; AGED; ARTICLE; ATTENTION; BRAIN FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; LATENT PERIOD; MALE; NEUROTRANSMISSION; PILOT STUDY; PSYCHOLOGIC TEST; TASK PERFORMANCE;

EID: 57649166231     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Riederer P: Patobiochemie der Vigilanz- and Antriebsstorungen - tierexperimentelle Daten. In: Vigilanz- und Antriebsstorungen - Ursachen und Behandlungsstrategien. Munich, MMV Medizin Verlag GmbH 1995, 27-36.
2. Kornhuber J, Weller M, Shoppmeyer K et al.: Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm 1994, 43, 91-104.
3. Meythaler JM, Brunner RC, Johnson A et al.: Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehab 2002, 17(4), 300-313.
4. Kugler J: Die Beeinflussung von Vigilanz und Bewusstsein durch Aminoadamantinsulfat. Acta Neurol 1975, 2, 43-51.
5. Saniova B, Drobny M, Kneslowa L et al.: The outcome of patients with severe head injuries treated with amantadine sulphate. J Neural Transm 2004, 111, 511-514.
6. Steube D, Gortelmeyer R: Amantadinsulphat zur Vigilanzbeeinflussung bei schweren erworbenen Himschaden. Neurol Rehab 2000, 6, 307-312.
7. Jorg J: Aetiologie, Klinik und Therapie von Vigilanz - und Antriebsstorungen. In: Vigilanz- und Antriebsstorungen - Ursachen und Behandlungsstrategien. Munich, MMV Medizin Verlag GmbH 1995, 7-26.
8. Semlitsch Hv, Anderer P, Saletu B: Topographic mapping of long latency "cognitive" event-related potentials (P300): a double blind, placebo-controlled study with amantadine in mild dementia. J Neural Transm Park Dis Dement Sect 1992, 4, 319-336.
9. Gehlen W: Vigilanzsteigerungen bei himorganischem Psychosyndrom. TW Neurol Psychiatr 1993, 7, 301-303.
10. Barret AM, Eslinger PJ: Amantadine for adynamic speech: possible benefit for aphasia? Am J Phys Med Rehabil 2007, 86, 8, 605-612.
11. Arciniegas DB, Frey KL, Anderson CA et al.: Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy. Brain Inj 2004, 18, 12, 1309-1318.
12. Reitan RM: Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958, 8, 271-276.
13. Polich J, Ehlers C, Otis S, Mandell AJ, Bloom FE: P300 latency reflects the degree of cognitive decline in dementing illness. Electroenceph Clin Neurophysiol 1986, 63, 138-144.
14. Goodin DS: Clinical utility of long latency "cognitive" event-related potentials (P3): the pros. Electroenceph Clin Neurophysiol 1990, 76, 2-5.
15. Tachibana H, Toda K, Sugita M: Event-related potentials in patients with multiple lacunar infarcts. Gerontology 1992, 38, 322-329.
16. Korpelainen JT, Kauhanen MI, Tolonen U et al.: Auditory P300 event-related potential in minor ischemic stroke. Acta Neurol Scand 2000, 101, 202-208.
17. Kugler CF, Vlajic P, Funk H et al.: The event-related P300 potential approach to cognitive functions of nondemented patients with cerebral and peripheral arteriosclerosis. J Am Geriatr Soc 1995, 43, 1228-1236.
18. Van Harten B, Laman DM, Van Duijn H et al.: The auditory oddball paradigm in patients with vascular cognitive impairment: a prolonged latency of the N2 complex. Dement Geriatr Cogn Disord 2006, 21, 322-327.
19. Reis J, John D, Heimeroth A, Mueller HH et al.: Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology 2006, 31(12), 2758-2766.
20. Korostenskaja M, Nikulin VV, Kicić D et al.: Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull 2007, 30, 275-283.